Get the Stockscreener App
0.419
6.31%
-0.0282
After Hours:
.41
-0.009
-2.15%
Leap Therapeutics Inc stock is traded at $0.419, with a volume of 934.22K.
It is down -6.31% in the last 24 hours and down -21.46% over the past month.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.
See More
Previous Close:
$0.4472
Open:
$0.444
24h Volume:
934.22K
Relative Volume:
0.27
Market Cap:
$17.36M
Revenue:
$1.50M
Net Income/Loss:
$-64.59M
P/E Ratio:
-0.2509
EPS:
-1.67
Net Cash Flow:
$-55.17M
1W Performance:
-14.37%
1M Performance:
-21.46%
6M Performance:
-0.31%
1Y Performance:
-88.80%
1-Day Range:
$0.411
$0.4638
1-Week Range:
$0.411
$0.5698
52-Week Range:
$0.2223
$3.92
Leap Therapeutics Inc Stock (LPTX) Company Profile
Name
Leap Therapeutics Inc
Sector
Industry
Phone
617 252 4343
Address
47 THORNDIKE STREET, CAMBRIDGE, MA
Compare LPTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.419 | 25.33M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-29-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-04-21 | Initiated | Mizuho | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Nov-15-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Sep-13-19 | Resumed | Raymond James | Outperform |
| Mar-07-17 | Initiated | Ladenburg Thalmann | Buy |
View All
Leap Therapeutics Inc Stock (LPTX) Latest News
Can Leap Therapeutics Inc. stock sustain institutional interestJuly 2025 Earnings & Precise Buy Zone Identification - newser.com
What insider trading reveals about Leap Therapeutics Inc. stockJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
Is Leap Therapeutics Inc. (5MC) stock undervalued historicallyQuarterly Profit Summary & Consistent Growth Stock Picks - newser.com
[DEF 14A] LEAP THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan
Trend analysis for Leap Therapeutics Inc. this weekQuarterly Profit Summary & Long-Term Safe Investment Ideas - newser.com
What valuation ratios show for Leap Therapeutics Inc. (5MC) stockSwing Trade & Daily Stock Momentum Reports - newser.com
Identifying reversal signals in Leap Therapeutics Inc.July 2025 Levels & Risk Controlled Daily Plans - newser.com
What consensus target says about Leap Therapeutics Inc. (5MC) stockJuly 2025 Opening Moves & Verified Chart Pattern Signals - newser.com
Tools to assess Leap Therapeutics Inc.’s risk profile2025 Market Overview & Fast Moving Stock Trade Plans - newser.com
Will Leap Therapeutics Inc. (5MC) stock sustain uptrend momentumWeekly Profit Recap & High Win Rate Trade Tips - newser.com
Why hedge funds are buying Leap Therapeutics Inc. stock2025 Geopolitical Influence & Low Risk High Reward Ideas - newser.com
Why Leap Therapeutics Inc. stock is popular among millennialsPortfolio Gains Report & Risk Controlled Daily Plans - newser.com
Can swing trading help recover from Leap Therapeutics Inc. lossesJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
How Leap Therapeutics Inc. (5MC) stock performs during market turbulenceTrade Volume Report & Low Risk Growth Stock Ideas - newser.com
How strong is Leap Therapeutics Inc. stock balance sheetJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Forecasting Leap Therapeutics Inc. price range with options dataInsider Buying & Free Verified High Yield Trade Plans - newser.com
Can Leap Therapeutics Inc. stock continue upward trend2025 Growth vs Value & Risk Managed Investment Entry Signals - newser.com
Will Leap Therapeutics Inc. stock outperform growth indexes2025 Volume Leaders & Fast Entry Momentum Alerts - newser.com
What RSI levels show for Leap Therapeutics Inc. (5MC) stockQuarterly Portfolio Report & Smart Money Movement Alerts - newser.com
Is Leap Therapeutics Inc. (5MC) stock a defensive play amid uncertaintyInsider Buying & Weekly Stock Performance Updates - newser.com
Will Leap Therapeutics Inc. (5MC) stock remain on Wall Street radar2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
Published on: 2025-10-31 05:04:37 - newser.com
Will Leap Therapeutics Inc. price bounce be sustainable2025 Market Overview & Risk Managed Investment Entry Signals - newser.com
Will Leap Therapeutics Inc. outperform the marketLong Setup & Expert Approved Momentum Trade Ideas - newser.com
Leap Therapeutics Inc Stock (LPTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):